Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02790515
What this trial is testing

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myeloid Sarcoma+4 more
St. Jude Children's Research Hospital 170
Testing effectiveness (Phase 2)Ended earlyNCT06018129
What this trial is testing

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaNon-Hodgkin Lymphoma
Genmab 9
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06931613
What this trial is testing

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaChildrenNivolumab+1 more
St. Petersburg State Pavlov Medical University 20
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Testing effectiveness (Phase 2)Study completedNCT02572167
What this trial is testing

Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Seagen Inc. 93
Testing effectiveness (Phase 2)Ended earlyNCT02594163
What this trial is testing

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma RefractoryFollicular B-cell Non-Hodgkin's Lymphoma
Seagen Inc. 25
Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Early research (Phase 1)Study completedNCT01221571
What this trial is testing

Assess AFM13 in Patients With Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Affimed GmbH 28
Early research (Phase 1)Study completedNCT03236857
What this trial is testing

The Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Who this might be right for
MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)+2 more
AbbVie 143
Early research (Phase 1)Looking for participantsNCT05054257
What this trial is testing

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
Institute of Hematology and Blood Transfusion, Czech Republic 10
Testing effectiveness (Phase 2)Study completedNCT03456726
What this trial is testing

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT02939014
What this trial is testing

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Who this might be right for
Hodgkin DiseaseLymphoma, Large-Cell, Anaplastic
Takeda 39
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Testing effectiveness (Phase 2)Ended earlyNCT00112723
What this trial is testing

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT03277729
What this trial is testing

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+20 more
Fred Hutchinson Cancer Center 53
Early research (Phase 1)Active Not RecruitingNCT03434769
What this trial is testing

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Benjamin Tomlinson 31
Testing effectiveness (Phase 2)Ended earlyNCT00372905
What this trial is testing

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Who this might be right for
Lymphoma
Northwestern University 18
Early research (Phase 1)Study completedNCT00944905
What this trial is testing

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
Renal Cell CarcinomaNon-hodgkin's Lymphoma
Bristol-Myers Squibb 46
Next Page